Market Research Report

Product code

1063757

Precision Medicine Software Developers Market by Target Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), Key Geographical Regions (North America, Europe, Asia-Pacific)

Published: January 31, 2022 |

Roots Analysis | 176 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

Title:
Precision Medicine Software Developers
Market by Target Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), Key Geographical Regions (North America, Europe, Asia-Pacific) and Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies): Industry Trends and Global Forecasts, 2021-2031.

Example Insights:

Overview

Various studies have indicated that the genetic composition of two individuals is unlikely to be similar. This can be attributed to the fact that the genetic makeup of an individual is influenced by various factors, such as family history, as well as environmental and health conditions. Therefore, one treatment cannot be expected to be successful in every patient suffering from the same disorder. It is worth highlighting that the inability to report a health issue to a medical practitioner in its initial stage is expected to cost productivity losses worth over USD 40-90 billion, each year. Further, frequent hospitals visits can cause additional financial burden on patients. In order to mitigate the aforementioned challenges, healthcare professionals are shifting towards the use of personalized / precision medicine. This approach, as opposed to the one-size-fits-all approach, enables healthcare professionals to offer a precise treatment option for a specific disease that is likely to prove effective for a group of individuals. This domain has the ability to reduce treatment burden across many therapeutic areas including oncological disorders, rheumatology disorders.

Given the various advantages offered by precision medicine, healthcare organizations are gradually becoming more interested in adopting such solutions. Further, with the advent of bioinformatics and artificial intelligence tools, there has been a significant rise in the adoption of such applications. For instance, in June 2020, Infosys launched its proprietary personalized medicine solution, equipped with latest SAP S/4HANA® technology, to gain intelligent insights to deliver personalized experience to patients. It is worth highlighting that precision medicine software solutions are widely used by healthcare providers for the diagnosis, as well as prognosis, of the disease. However, the scope is being continuously expanded in order to include the prevention and recovery of life threatening diseases. At present, several software applications integrate clinical and diagnostic data, along with financial data, offering deeper and precise insights to healthcare providers, as well as helping them improve patient outcomes. Players engaged in the development of precision medicine software applications have observed a significant growth over the past few years. More than 120 software solutions have been developed and are available commercially. It is also worth highlighting that over USD 2 billion has been invested in this domain by various stakeholders in the last four years. As a result of the rising adoption and preference for precision medicine software applications, coupled to the ongoing efforts of software providers to further improve the current software solutions, we believe that the precision medicine software services market is likely to witness significant growth in the foreseen future.

Scope of the Report

The "Precision Medicine Software Developers Market by Target Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), Key Geographical Regions (North America, Europe, Asia-Pacific) and Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies): Industry Trends and Global Forecasts, 2021-2031" report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of precision medicine software in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features the following:

A detailed overview of the current market landscape of precision medicine software developers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of platforms (cloud-based and on-premises) , purpose of software (diagnosis, analysis, treatment) , type of data (genomic data, clinical data, image data and others) , therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders) and types of end users (healthcare providers, research and government institutes, pharmaceutical and biotech companies) .

Elaborate profiles of key players engaged in the development of precision medicine software applications. Each profile features a brief overview of the company, along with its information on technology / service portfolio, recent developments and an informed future outlook.

A detailed analysis of the various patents that have been filed / granted within this domain, since 2018. It highlights the key trends associated with these patents across several relevant parameters, such as publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of organization, leading patent assignees and most active players (in terms of number of patents filed) . In addition, it includes a patent benchmarking analysis and patent valuation.

An analysis of the recent partnerships inked between various players engaged in this domain, during the period 2018-2021, based on several relevant parameters, such as year of partnership, type of partnership model adopted, regional distribution (continent and country-wise) and most active players (in terms of number of partnerships inked).

A detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO) ) undertaken by companies engaged in this domain, during the period 2018-2021.

A detailed analysis based on a proprietary 2x2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution, along with a Harvey ball analysis.

One of the key objectives of the report was to estimate the existing market size and future potential of precision medicine software developers, over the coming decade. Further, we have provided an informed estimate of the market's evolution, during the period 2021-2031, based on several relevant parameters, such as adoption trends, and expected price variations for these products. The report features the likely distribution of the current and forecasted opportunity within the precision medicine software market across [A] Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), [B] Key Geographical Regions (North America, Europe, Asia-Pacific) , [C] Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies) .

All actual figures have been sourced and analyzed from publicly available information forums and secondary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

Who are the key players engaged in the development of precision medicine software applications?

Which type of platform is more likely to outreach the market in the near future?

Which companies are actively engaged in the development of precision medicine software applications?

What are the major therapeutic areas targeted by various precision medicine software applications?

What kind of partnership models are commonly adopted by industry stakeholders?

Who are the key investors in this domain?

Who are the target users of precision medicine software applications?

What are the different types of data being handled by precision medicine software developers?

What is the main purpose for using precision medicine software applications?

How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of precision medicine software market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to precision medicine and precision medicine software solutions and its historical evolution. It further includes a brief outline on the need for software solutions, along with information on the various patient monitoring related services offered by players engaged in this domain. Furthermore, it highlights prevalent advantages and key challenges associated with precision medicine software, featuring details related to the current and future trends in the domain.

Chapter 4 provides a detailed overview of the overall market landscape of players engaged in providing precision medicine software solutions, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of platforms (cloud-based, on-premises), purpose of software (diagnosis, analysis, treatment), type of data handled (genomic data, clinical data, image data, omics data), therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders), types of end users (healthcare providers, research and government institutes, pharmaceutical and biotech companies).

Chapter 5 includes detailed profiles of the key players that are active in this domain. Each profile includes a brief overview of the company, its information on technology / service portfolio, recent developments and an informed future outlook.

Chapter 6 features a comprehensive company competitiveness analysis, highlighting prominent players among two peer groups (North America and Europe and Asia Pacific) that we came across during our research. The chapter provides a comparative analysis of the companies within each peer group on the basis of supplier strength (considering a company's overall experience in the industry).

Chapter 7 provides an overview of the various patents related to precision medicine software solutions that have been filed / granted, since 2018. It highlights the key trends associated with these patents across various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of organization, leading patent assignees and the leading players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 8 features an analysis of the recent partnerships inked between precision medicine software developers, during the period 2018-2021 Additionally, it includes a brief description of the various types of partnerships models (such as product / software integration agreement, service alliance, service agreement, product / software development agreement, full business acquisition, product / software distribution agreement, product / software utilization agreement, and product portfolio acquisition) that have been adopted by stakeholders engaged in this domain, during the period 2018-2021.

Chapter 9 provides an analysis of various investments made by players engaged in this domain based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (such as, venture capital, private equity, secondary offerings, debt, initial public offering (IPO), other equity, seed, grant, and others), along with information on the most active players (in terms of number of funding instances and amount raised) and most active investors (in terms of number of funding instances).

Chapter 10 features a proprietary 2x2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

Chapter 11 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders), [B] key geographical regions (North America, Europe, Asia-Pacific) and [C] end user (healthcare providers, research & government institutes, pharmaceutical & biotech companies).

Chapter 12 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall precision medicine software developers.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

2.1. Chapter Overview

3. INTRODUCTION

3.1. Chapter Overview
3.2. Overview of Precision Medicine
- 3.2.1. Evolution of Precision Medicine
- 3.2.2. Novel Approaches in Precision Medicine
  - 3.2.2.1 Biomarkers
    - 3.2.2.1.1. Biomarkers and Decision Making
    - 3.2.2.1.2. Genomics, Epigenetics and MicroRNAs as Emerging Biomarkers
    - 3.2.2.1.3 Biomarker Multiplexing
    - 3.2.2.1.4. Digital Biomarkers
  - 3.2.2.2. Metabolomics
3.3. Key Technology Platforms
- 3.3.1. Cloud Based
- 3.3.2. On-Premises
3.4. Key Challenges Faced by Precision Medicine Software Developers
- 3.4.1. Unprecedented Data Volumes
- 3.4.2. Interpreting Data Deluge at Individual Level
- 3.4.3. Incorporation of Solutions in the Clinic
3.5. Application Areas
- 3.5.1. Therapeutic Areas
  - 3.5.1.1. Oncological Disorders
  - 3.5.1.2. Cardiovascular Disorders
  - 3.5.1.3. Respiratory Disorders
  - 3.5.1.4. Rare Disorders
- 3.5.2. Pharmacogenomics
  - 3.5.2.1. Genetic Variations
  - 3.5.2.2. Drug Development
3.6. Benefits of Precision Medicine over Traditional Treatment Modalities
- 3.6.1. Benefits to Patients
- 3.6.2. Benefits to Healthcare Providers
3.7. Future Perspectives

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Precision Medicine Software Developers: Overall Market Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Region
- 4.2.4. Analysis by Type of Platform
- 4.2.5. Analysis by Purpose of Software Applications
- 4.2.6. Analysis by Type of Data Handled
- 4.2.7. Analysis by Therapeutic Area
- 4.2.8. Analysis by Type of End User
4.3. Key Insights

5. COMPANY PROFILES

5.1. Chapter Overview
5.2. Precision Medicine Software Developers
- 5.2.1. Ariel Precision Medicine
  - 5.2.1.1. Company Overview
  - 5.2.1.2. Product Portfolio
  - 5.2.1.3. Recent Developments and Future Outlook
- 5.2.2. C2i Genomics
  - 5.2.2.1. Company Overview
  - 5.2.2.2. Product Portfolio
  - 5.2.2.3. Recent Developments and Future Outlook
- 5.2.3. Genedata
  - 5.2.3.1. Company Overview
  - 5.2.3.2. Product Portfolio
  - 5.2.3.3. Recent Developments and Future Outlook
- 5.2.4. Inspirata
  - 5.2.4.1. Company Overview
  - 5.2.4.2. Product Portfolio
  - 5.2.4.3. Recent Developments and Future Outlook
- 5.2.5. IQVIA
  - 5.2.5.1. Company Overview
  - 5.2.5.2. Product Portfolio
  - 5.2.5.3. Recent Developments and Future Outlook
- 5.2.6. SAP
  - 5.2.6.1. Company Overview
  - 5.2.6.2. Product Portfolio
  - 5.2.6.3. Recent Developments and Future Outlook
5.3. Additional Profiles
- 5.3.1. Fabric Genomics
  - 5.3.1.1. Company Overview
  - 5.3.1.2. Product Portfolio
  - 5.3.1.3. Recent Developments and Future Outlook
- 5.3.2. GenomOncology
  - 5.3.2.1. Company Overview
  - 5.3.2.2. Product Portfolio
  - 5.3.2.3. Recent Developments and Future Outlook
- 5.3.3. Human Longevity
  - 5.3.3.1. Company Overview
  - 5.3.3.2. Product Portfolio
  - 5.3.3.3. Recent Developments and Future Outlook
- 5.3.4. SOPHiA GENETICS
  - 5.3.4.1. Company Overview
  - 5.3.4.2. Product Portfolio
  - 5.3.4.3. Recent Developments and Future Outlook
- 5.3.5. Syapse
  - 5.3.5.1. Company Overview
  - 5.3.5.2. Product Portfolio
  - 5.3.5.3. Recent Developments and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview
6.2. Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Precision Medicine Software Developers
- 6.4.1. Company Competitiveness Analysis: Large and Very Large Companies
- 6.4.2. Company Competitiveness Analysis: Mid-sized Companies
- 6.4.3. Company Competitiveness Analysis: Small Companies

7. PATENT ANALYSIS

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Precision Medicine Software Developers: Patent Analysis
- 7.3.1. Analysis by Type of Patent
- 7.3.2. Analysis by Publication Year
- 7.3.4. Analysis by Publication Year and Granted Patents
- 7.3.5. Analysis by Geography (Continent-wise)
- 7.3.6. Analysis by Region (Country-wise)
- 7.3.7. Analysis by Type of Company
  - 7.3.7.1 Industry Players
  - 7.3.7.2 Non-Industry Players
- 7.3.8. Analysis by Patent Age
- 7.3.9. Analysis by CPC Classification
- 7.3.10. Analysis by Emerging Focus Area
- 7.3.11. Most Active Players: Analysis by Number of Patents
- 7.3.12. Most Active Inventors: Analysis by Number of Patents
- 7.3.13. Patent Benchmarking Analysis
- 7.3.14. Patent Valuation Analysis
- 7.3.15. Analysis by Citation
- 7.3.16. Analysis by Type of Legal Status
  - 7.3.16.1. Analysis by Legal Status
  - 7.3.16.2. Analysis by Geography and Legal Status

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Chapter Overview
8.2. Partnership Models
8.3. Precision Medicine Software Developers: Recent Partnerships and Collaborations
- 8.3.1. Analysis by Year of Partnership
- 8.3.2. Analysis by Type of Partnership
- 8.3.3. Analysis by Year and Type of Partnership
- 8.3.4. Analysis by Focus Area
- 8.3.5. Analysis by Year of Partnership and Focus Area
- 8.3.6. Analysis by Type of Partnership and Focus Area
- 8.3.7. Analysis by Therapeutic Area
- 8.3.8. Analysis by Type of Partnership and Type of Platform
- 8.3.9. Analysis by Type of Partnership and Type of Data Handled
- 8.3.10. Analysis by Region
  - 8.3.10.1. Continent-wise Distribution
  - 8.3.10.2. Intercontinental and Intracontinental Distribution
  - 8.3.10.3. Country-wise Distribution
- 8.3.11. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS

9.1. Chapter Overview
9.2. Types of Funding
9.3. Precision Medicine Software Developers: Funding and Investment Analysis
- 9.3.1 Analysis by Year, Type of Funding and Amount Invested
- 9.3.2. Analysis of Instances by Year
- 9.3.3. Analysis of Amount Invested by Year
- 9.3.4. Analysis of Amount Invested by Type of Funding
  - 9.3.4.1. Analysis of Instances and Total Amount Invested by Type of Funding
  - 9.3.4.2. Analysis of Instances and Total Amount Invested by Type of Venture Capital Funding
- 9.3.5. Analysis by Geography
  - 9.3.5.1. Continent-wise Distribution
  - 9.3.5.2. Country-wise Distribution
- 9.3.6. Analysis of Amount Invested by Geography
- 9.3.7. Analysis of Instances by Year and Type of Funding
- 9.3.8. Analysis of Instances by Type of Investor
- 9.3.9. Analysis of Instances by Purpose of Funding
- 9.3.10. Analysis of Instances by Therapeutic Area
- 9.3.11. Analysis of Instances by Type of Data Handled
- 9.3.12. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
- 9.3.13. Key Investors: Analysis by Number of Instances
- 9.3.14. Funding and Investment Summary

10. ATTRACTIVENESS COMPETETIVENESS MATRIX

10.1. Chapter Overview
10.2. AC Matrix: Overview
- 10.2.1. Strong Business Segments
- 10.2.2. Average Business Segments
- 10.2.3. Weak Business Segments

11. MARKET FORECAST

11.1. Chapter Overview
11.2. Forecast Methodology and Assumptions
11.3. Global Precision Medicine Software Developers Market, 2021-2031
11.4. Precision Medicine Software Developers Market, 2021-2031: Analysis by Therapeutic Area
- 11.4.1. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2031
- 11.4.2. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2031
- 11.4.3. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2031
- 11.4.4. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2031
11.5. Precision Medicine Software Developers Market, 2021-2031: Analysis by Geography
- 11.5.1. Precision Medicine Software Developers Market in North America, 2021-2031
- 11.5.2. Precision Medicine Software Developers Market in Europe, 2021-2031
- 11.5.3. Precision Medicine Software Developers Market in Asia-Pacific, 2021-2031
11.6. Precision Medicine Software Developers Market, 2021-2031: Analysis by Type of End User
- 11.6.1. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2031
- 11.6.2. Precision Medicine Software Developers Market for Researchers and Government Institutes, 2021-2031
- 11.6.3. Precision Medicine Software Developers Market for Pharmaceutical and Biotech Companies, 2021-2031

12. SWOT ANALYSIS

12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
12.7. Concluding Remarks

13. CONCLUDING REMARKS

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES

List Of Figures

Figure 2.1 Executive Summary: Developer Landscape
Figure 2.2 Executive Summary: Market Overview
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast
Figure 3.1. Evolution of Precision Medicine
Figure 4.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Figure 4.2. Precision Medicine Software Developers: Distribution by Company Size
Figure 4.3. Precision Medicine Software Developers: Distribution by Region
Figure 4.4. Precision Medicine Software Developers: Distribution by Location of Headquarters
Figure 4.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Figure 4.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Region
Figure 4.7. Precision Medicine Software Applications: Distribution by Type of Platform
Figure 4.8. Precision Medicine Software Applications: Distribution by Purpose of Software Applications
Figure 4.9. Precision Medicine Software Applications: Distribution by Type of Data Handled
Figure 4.10. Precision Medicine Software Applications: Distribution by Therapeutic Area
Figure 4.11. Precision Medicine Software Applications: Distribution by Type of Data Handled and Therapeutic Area
Figure 4.12. Precision Medicine Software Applications: Distribution by Regulatory Accreditation Received
Figure 4.13. Precision Medicine Software Applications: Distribution by Status of Software Applications
Figure 4.14. Precision Medicine Software Applications: Distribution by Status of Software Applications and Region
Figure 4.15. Precision Medicine Software Applications: Distribution by Therapeutic Area and Status of Software Applications
Figure 4.16. Precision Medicine Software Applications: Distribution by Type of Data Handled and Status of Software Applications
Figure 4.17. Precision Medicine Software Applications: Distribution by Type of End-User
Figure 4.18. Precision Medicine Software Developers: Most Active Players, Distribution by Number of Software Applications
Figure 6.1. Company Competitiveness: Small Companies
Figure 6.2. Company Competitiveness: Mid-sized Companies
Figure 6.3. Company Competitiveness: Large and Very Large Companies
Figure 6.4. Company Competitiveness: Companies in North America
Figure 6.5. Company Competitiveness: Companies in Europe, Asia-Pacific and RoW
Figure 6.6. Company Competitiveness: Most Active Players
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Distribution by Publication Year
Figure 7.3. Patent Analysis: Distribution of Granted Patents by Publication Year
Figure 7.4. Patent Analysis: Distribution by Geography (Continent-wise)
Figure 7.5. Patent Analysis: Distribution of Players in North America (Region-wise)
Figure 7.6. Patent Analysis: Distribution of Players in Europe (Region-wise)
Figure 7.7. Patent Analysis: Distribution of Players in Asia-Pacific (Region-wise)
Figure 7.8. Patent Analysis: Distribution by Type of Company
Figure 7.9. Patent Analysis: Distribution by Patent Age
Figure 7.10. Patent Analysis: Distribution by CPC Classification
Figure 7.11. Patent Analysis: Distribution by Emerging Focus Area
Figure 7.12. Most Active Players: Distribution by Number of Patents
Figure 7.13. Most Active Inventors: Distribution by Number of Patents
Figure 7.14. Patent Analysis: Benchmarking
Figure 7.15. Patent Analysis: Patent Relative Valuation
Figure 7.16. Patent Analysis: Distribution by Patent Citation
Figure 7.17. Patent Analysis: Distribution by Legal Status
Figure 7.18. Patent Analysis: Distribution by Legal Status and Geography
Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4. Partnerships and Collaborations: Distribution by Focus Area
Figure 8.5. Partnerships and Collaborations: Distribution by Year of Partnership and Focus
Figure 8.6. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.7. Partnerships and Collaborations: Distribution by Focus Area and Therapeutic Area
Figure 8.8. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Data Handled
Figure 8.9. Partnerships and Collaborations: Distribution by Year and Type of Software Applications
Figure 8.10. Partnerships and Collaborations: Distribution by Geography (Continent-wise)
Figure 8.11. Partnerships and Collaborations: Distribution by Geography (Country-wise)
Figure 8.12. Most Active Players: Distribution by Number of Partnerships
Figure 9.1. Funding and Investments: Distribution by Year of Funding
Figure 9.2. Funding and Investments: Distribution of Amount Invested by Year
Figure 9.3. Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 9.4. Funding and Investments: Distribution of Instances and Total Amount Invested by Type of Funding
Figure 9.5. Funding and Investments: Distribution of Instances and Total Amount Invested by Type of Venture Capital Funding
Figure 9.6. Funding and Investments: Distribution of Instances and Geography (Continent-wise)
Figure 9.7. Funding and Investments: Distribution of Instances and Geography (Country-wise)
Figure 9.8. Funding and Investments: Distribution of Amount Invested by Geography
Figure 9.9. Funding and Investments: Distribution of Instances by Year and Type of Funding
Figure 9.10. Funding and Investments: Distribution of Instances by Therapeutic Area
Figure 9.11. Funding and Investments: Distribution of Instances by Type of Data Handled
Figure 9.12. Most Active Players: Distribution by Number of Funding Instances and Amount Invested
Figure 9.13. Most Active Investors: Distribution by Number of Funding Instances
Figure 10.1. AC Matrix: North America Scenario
Figure 10.2. AC Matrix: Europe Scenario
Figure 10.3. AC Matrix: Asia Pacific and RoW Scenario
Figure 11.1. Global Precision Medicine Software Developers Market, 2021-2031 (USD Million)
Figure 11.2. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2021-2031 (USD Million)
Figure 11.3. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2031 (USD Million)
Figure 11.4. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2031 (USD Million)
Figure 11.5. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2031 (USD Million)
Figure 11.6. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2031 (USD Million)
Figure 11.7. Precision Medicine Software Developers Market: Distribution by Geography, 2021-2031 (USD Million)
Figure 11.8. Precision Medicine Software Developers Market in North America, 2021-2031 (USD Million)
Figure 11.9. Precision Medicine Software Developers Market in Europe, 2021-2031 (USD Million)
Figure 11.10. Precision Medicine Software Developers Market in Asia-Pacific and RoW, 2021-2031 (USD Million)
Figure 11.11. Precision Medicine Software Developers Market: Distribution by Type of End-User, 2021-2031 (USD Million)
Figure 11.12. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2031 (USD Million)
Figure 11.13. Precision Medicine Software Developers Market for Research and Government Institutes, 2021-2031 (USD Million)
Figure 11.14. Precision Medicine Software Developers Market for Pharmaceutical and Biotech Companies, 2021-2031 (USD Million)
Figure 12.1. Precision Medicine Software Developers: SWOT Analysis
Figure 12.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1. Concluding Remarks: Current Market Landscape
Figure 13.2. Concluding Remarks: Recent Partnerships
Figure 13.3. Concluding Remarks: Funding Analysis
Figure 13.4. Concluding Remarks: Cost Saving Analysis
Figure 13.5. Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1. Precision Medicine Software Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 4.2. Precision Medicine Software Applications: Information on Software Applications, Status of Software Applications, HIPAA Compliance
Table 4.3. Precision Medicine Software Applications: Information on Software Applications Specification and Software Applications Purpose
Table 4.4. Precision Medicine Software Applications: Information on Type of Data Handled
Table 4.5. Precision Medicine Software Applications: Information on Therapeutic Area
Table 4.6. Precision Medicine Software Applications: Information on Type of End-User
Table 5.1. SAP: Company Overview
Table 5.2. SAP: Product Portfolio
Table 5.3. IQVIA: Company Overview
Table 5.4. IQVIA: Product Portfolio
Table 5.5. IQVIA: Recent Developments and Future Outlook
Table 5.6. Inspirata: Company Overview
Table 5.7. Inspirata: Product Portfolio
Table 5.8. Genedata: Company Overview
Table 5.9. Genedata: Product Portfolio
Table 5.10. Genedata: Recent Developments and Future Outlook
Table 5.11. Ariel Precision Medicine: Company Overview
Table 5.12. Ariel Precision Medicine: Product Portfolio
Table 5.13. Ariel Precision Medicine: Recent Developments and Future Outlook
Table 5.14. C2i Genomics: Company Overview
Table 5.15. C2i Genomics: Product Portfolio
Table 5.16. C2i Genomics: Recent Developments and Future Outlook
Table 5.17. Syapse: Company Overview
Table 5.18. Syapse: Product Portfolio
Table 5.19. Syapse: Recent Developments and Future Outlook
Table 5.20. Fabric Genomics: Company Overview
Table 5.21. Fabric Genomics: Product Portfolio
Table 5.22. GenomOncology: Company Overview
Table 5.23. GenomOncology: Product Portfolio
Table 5.24. SOPHiA GENETICS: Company Overview
Table 5.25. SOPHiA GENETICS: Product Portfolio
Table 5.26. SOPHiA GENETICS: Recent Developments and Future Outlook
Table 5.27. Human Longevity: Company Overview
Table 5.28. Human Longevity: Product Portfolio
Table 5.29. Human Longevity: Recent Developments and Future Outlook
Table 7.1. Patent Analysis: List of Top CPC Symbols
Table 7.2. Patent Analysis: Summary of Benchmarking Analysis
Table 7.3. Patent Analysis: Information on Patent Categorization based on Weighted Scores
Table 7.4. Patent Analysis: List of Leading Patents (in terms of highest relative valuation)
Table 8.1. Partnerships and Collaborations: Information on Partner, Year of Partnership, and Type of Partnership, 2018-2021
Table 8.2. Partnerships and Collaborations: Information on Focus Area and Therapeutic Area
Table 9.1. Fundings and Investments: Information on Type of Funding, Year of Investment, Amount Invested and Lead Investors, 2018-2021
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 9.3 Funding and Investment Analysis: Summary of Venture Capital Round
Table 9.4 Fundings and Investments: Information on Year of Funding, Location of Headquarters of Recipients, Software Applications, Type of Software Applications and Focus Area
Table 14.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Table 14.2. Precision Medicine Software Developers: Distribution by Company Size
Table 14.3. Precision Medicine Software Developers: Distribution by Region
Table 14.4. Precision Medicine Software Developers: Distribution by Location of Headquarters
Table 14.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Table 14.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Region
Table 14.7. Precision Medicine Software Developers: Distribution by Type of Platform
Table 14.8. Precision Medicine Software Developers: Distribution by Purpose of Software Applications
Table 14.9. Precision Medicine Software Developers: Distribution by Type of Data Handled
Table 14.10. Precision Medicine Software Developers: Distribution by Therapeutic Area
Table 14.11. Precision Medicine Software Developers: Distribution by Type of Data Handled and Therapeutic Area
Table 14.12. Precision Medicine Software Developers: Distribution by Regulatory Accreditation Received
Table 14.13. Precision Medicine Software Developers: Distribution by Status of Software Applications
Table 14.14. Precision Medicine Software Developers: Distribution by Status of Software Applications and Region
Table 14.15. Precision Medicine Software Developers: Distribution by Therapeutic Area and Status of Software Applications
Table 14.16. Precision Medicine Software Developers: Distribution by Type of Data Handled and Status of Software Applications
Table 14.17. Precision Medicine Software Developers: Distribution by Type of End-User
Table 14.18. Precision Medicine Software Developers: Most Active Players: Distribution by Number of Software Applications
Table 14.19. Company Competitiveness: Small Companies
Table 14.20. Company Competitiveness: Mid-sized Companies
Table 14.21. Company Competitiveness: Large and Very Large Companies
Table 14.22. Company Competitiveness: Companies in North America
Table 14.23. Company Competitiveness: Companies in Europe, Asia-Pacific and RoW
Table 14.24. Company Competitiveness: Most Active Players
Table 14.25. Patent Analysis: Distribution by Type of Patent
Table 14.26. Patent Analysis: Distribution by Publication Year
Table 14.27. Patent Analysis: Distribution of Granted Patents by Publication Year
Table 14.28. Patent Analysis: Distribution by Geography (Continent-wise)
Table 14.29. Patent Analysis: Distribution of Players in North America (Region-wise)
Table 14.30. Patent Analysis: Distribution of Players in Europe (Region-wise)
Table 14.31. Patent Analysis: Distribution of Players in Asia-Pacific (Region-wise)
Table 14.32. Patent Analysis: Distribution by Type of Company
Table 14.33. Patent Analysis: Distribution by Patent Age
Table 14.34. Patent Analysis: Distribution by CPC Classification
Table 14.35. Patent Analysis: Distribution by Emerging Focus Area
Table 14.36. Patent Analysis: Most Active Players: Distribution by Number of Patents
Table 14.37. Patent Analysis: Most Active Inventors: Distribution by Number of Patents
Table 14.38. Patent Analysis: Benchmarking
Table 14.39. Patent Analysis: Patent Relative Valuation
Table 14.40. Patent Analysis: Distribution by Patent Citation
Table 14.41. Patent Analysis: Distribution by Legal Status
Table 14.42. Patent Analysis: Distribution by Legal Status and Geography
Table 14.43. Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.44. Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.45. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.46. Partnerships and Collaborations: Distribution by Focus Area
Table 14.47. Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
Table 14.48. Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.49. Partnerships and Collaborations: Distribution by Focus Area and Therapeutic Area
Table 14.50. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Data Handled
Table 14.51. Partnerships and Collaborations: Distribution by Year and Type of Software Applications
Table 14.52. Partnerships and Collaborations: Distribution by Geography (Continent-wise)
Table 14.53. Partnerships and Collaborations: Distribution by Geography (Country-wise)
Table 14.54. Most Active Players: Distribution by Number of Partnerships
Table 14.55. Funding and Investments: Distribution by Year of Funding
Table 14.56. Funding and Investments: Distribution of Amount Invested by Year
Table 14.57. Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 14.58. Funding and Investments: Distribution of Instances and Total Amount Invested by the Type of Funding
Table 14.59. Funding and Investments: Distribution of Instances and Total Amount Invested by Type of Venture Capital Funding
Table 14.60. Funding and Investments: Distribution Instances and Geography (Continent-wise)
Table 14.61. Funding and Investments: Distribution of Instances and Geography (Country-wise)
Table 14.62. Funding and Investments: Distribution of Amount Invested by Geography
Table 14.63. Funding and Investments: Distribution of Instances by Year and Type of Funding
Table 14.64. Funding and Investments: Distribution of Instances by Therapeutic Area
Table 14.65. Funding and Investments: Distribution of Instances by Type of Data Handled
Table 14.66. Most Active Players: Distribution by Number of Funding Instances and Amount Invested
Table 14.67. Most Active Investors: Distribution by Number of Funding Instances
Table 14.68. AC Matrix: North America Scenario
Table 14.69. AC Matrix: Europe Scenario
Table 14.70. AC Matrix: Asia Pacific and RoW Scenario
Table 14.71. Global Precision Medicine Software Developers Market, 2021-2031 (USD Million)
Table 14.72. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2021-2031 (USD Million)
Table 14.73. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2031 (USD Million)
Table 14.74. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2031 (USD Million)
Table 14.75. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2031 (USD Million)
Table 14.76. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2031 (USD Million)
Table 14.77. Precision Medicine Software Developers Market: Distribution by Geography, 2021-2031 (USD Million)
Table 14.78. Precision Medicine Software Developers Market in North America, 2021-2031 (USD Million)
Table 14.79. Precision Medicine Software Developers Market in Europe, 2021-2031 (USD Million)
Table 14.80. Precision Medicine Software Developers Market in Asia-Pacific and RoW, 2021-2031 (USD Million)
Table 14.81. Precision Medicine Software Developers Market: Distribution by Type of Type of End-User, 2021-2031 (USD Million)
Table 14.82. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2031 (USD Million)
Table 18.83. Precision Medicine Software Developers Market for Research and Government Institutes, 2021-2031 (USD Million)
Table 18.84. Precision Medicine Software Developers Market for Pharmaceutical and Biotech Companies, 2021-2031 (USD Million)